Literature DB >> 28407366

Screening children for pulmonary arteriovenous malformations: Evaluation of 18 years of experience.

Anna E Hosman1, Els M de Gussem2, Walter A F Balemans3, Andréanne Gauthier4, Cees J J Westermann1, Repke J Snijder1, Marco C Post5, Johannes J Mager1.   

Abstract

BACKGROUND: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant disease with multi-systemic vascular dysplasia. Early diagnosis through screening is important to prevent serious complications. How best to screen children of affected parents for pulmonary arteriovenous malformations (PAVMs) is often subject to debate. Transthoracic contrast echocardiogram (TTCE) is considered optimal in screening for PAVMs in adults. Guidelines for the screening of children are not specific, reflecting the lack of scientific evidence on the best method to use.
OBJECTIVE: Aims of this study are (i) to evaluate our current screening method, consisting of history, physical examination, pulse oximetry, and chest radiography and (ii) to assess whether postponing more invasive screening for PAVMs until adulthood is safe.
METHODS: This is a prospective observational cohort study using a patient database.
RESULTS: Over a period of 18 years (mean follow-up 9.21 years, SD 4.72 years), 436 children from HHT families were screened consecutively. A total of 175/436 (40%) children had a diagnosis of HHT. PAVMs were detected in 39/175 (22%) children, 33/39 requiring treatment by embolotherapy. None of the screened children suffered any PAVM-associated complications with this screening method.
CONCLUSION: This study shows that a conservative screening method during childhood is sufficient to detect large PAVMs and protect children with HHT for PAVM-related complications. Postponing TTCE and subsequent chest CT scanning until adulthood to detect any smaller PAVMs does not appear to be associated with major risk.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  ACVRL1; endoglin; hereditary hemorrhagic telangiectasia; pulmonary arteriovenous malformation; vascular disease

Mesh:

Year:  2017        PMID: 28407366     DOI: 10.1002/ppul.23704

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

Review 1.  Pulmonary Arteriovenous Malformations: What the Interventional Radiologist Should Know.

Authors:  Claire S Kaufman; Jamie McDonald; Heather Balch; Kevin Whitehead
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

2.  Pediatric thoracic mass lesions: Beyond the common.

Authors:  Gunes Orman; Prakash Masand; John Hicks; Thierry A G M Huisman; R Paul Guillerman
Journal:  Eur J Radiol Open       Date:  2020-06-11

3.  Pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia: a longitudinal study.

Authors:  Katie L Mowers; Lynn Sekarski; Andrew J White; R Mark Grady
Journal:  Pulm Circ       Date:  2018-06-19       Impact factor: 3.017

4.  Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence.

Authors:  Alexandra Kilian; Marianne S Clancy; Scott Olitsky; James R Gossage; Marie E Faughnan
Journal:  Vasc Med       Date:  2020-12-29       Impact factor: 3.239

5.  Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence.

Authors:  Els M de Gussem; Steven Kroon; Anna E Hosman; Johannes C Kelder; Martijn C Post; Repke J Snijder; Johannes J Mager
Journal:  J Clin Med       Date:  2020-11-06       Impact factor: 4.241

Review 6.  Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology.

Authors:  Sala Bofarid; Anna E Hosman; Johannes J Mager; Repke J Snijder; Marco C Post
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

7.  A Rare Case of Upper Gastrointestinal Bleeding: Osler-Weber-Rendu Syndrome.

Authors:  Anna Jargielo; Anna Rycyk; Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  Medicina (Kaunas)       Date:  2022-02-22       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.